Physiologic Monitoring of Antidepressant Treatment Response

• Status: Completed
• Trial end date: 2002-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Study Objectives:

• to identify neurophysiologic effects of venlafaxine treatment in normal controls using quantitative EEG (QEEG) cordance

• to examine the effects of venlafaxine on different rating scales measuring mood and anxiety (e.g., Ham-D, BDI, SCL-90, POMS-BI, Visual Analog Mood Scale, SSRS, SASS, Q-LES-Q and SF-36) as well as on measures of cognitive and psychosocial function (i.e., Stroop, PASAT, RAVLT, Trailmaking A and B, Digit-Symbol, Grooved Pegboard, Multidimensional Health Locus of Control, Temperament and Character Inventory, Interpersonal Support Evaluation List, Godin Leisure-Time Questionnaire, and Pittsburgh Sleep Quality Index) in normal control subjects, and the association of changes in cordance with changes in thinking and memory.

• to identify physiologic effects of venlafaxine treatment in normal controls using heart rate and immune function measures

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, Los Angeles
• Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Antidepressive Agents; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• All subjects will be between the ages of 18 - 65 and in good health (i.e., free of any medical condition known to affect brain function).

Exclusion Criteria:

• All subjects will have no serious medical illness such as high blood pressure, heart disease, renal impairment, or cirrhosis of the liver. This will be assured by making sure that prospective subjects have had a normal physical exam with in one year prior to entry of the study.

• The investigators will also exclude subjects who meet DSM-IV axis I criteria for a mood, anxiety, cognitive, or psychotic disorder on the basis of a SCID-P interview, as well as those meeting criteria for cluster A or B axis II diagnoses.

• Subjects with a history of current or past active suicidal ideation or suicide attempts will be excluded from the study.